Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, Sheetal Rao et al.|Nature Medicine|2024Cited by 452
Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cellsMay Daher, Katayoun Rezvani|Blood|2020Cited by 284
The Application of Natural Killer Cell Immunotherapy for the Treatment of CancerKatayoun Rezvani, Rayne H. Rouce|Frontiers in Immunology|2015Cited by 267
Targeting the αv integrin/TGF-β axis improves natural killer cell function against glioblastoma stem cellsHila Shaim, Katayoun Rezvani|Journal of Clinical Investigation|2021Cited by 245
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapyKris M. Mahadeo, Sajad Khazal, Hisham Abdel‐Azim et al.|Nature Reviews Clinical Oncology|2018Cited by 236